MK-677 (Ibutamoren) vs Somatropin (HGH)
A side-by-side research comparison of MK-677 (Ibutamoren) and Somatropin (HGH) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | MK-677 (Ibutamoren) | Somatropin (HGH) |
|---|---|---|
| Full name | Ibutamoren Mesylate (MK-677) | Recombinant Human Growth Hormone |
| Category | Growth Hormone | Growth Hormone |
| Status | Investigational | Prescription medication |
| Mechanism | Acts as ghrelin mimetic at GHS-R1a receptors in hypothalamus and pituitary. Excellent oral bioavailability and 24-hour duration. | Binds to GH receptors on target cells, triggering the JAK2/STAT5 signaling pathway. Stimulates hepatic IGF-1 production, promotes protein synthesis, mobilizes fatty acids from adipose tissue, and increases glucose output. |
| Molecular weight | 528.7 Da | 22,124 Da |
| Half-life | 24 hours | 2-3 hours (subcutaneous); tissue effects persist 9-17 hours via IGF-1 |
| Bioavailability | High (oral) | ~80% subcutaneous |
| Typical dose | 10-25 mg | 1-4 IU/day (anti-aging/wellness); 4-8 IU/day (performance) |
| Frequency | Once daily | Daily (split AM/PM for higher doses) |
| Route | Oral (capsule/liquid) | Subcutaneous injection |
MK-677 (Ibutamoren) reported benefits
- Oral administration
- Sustained 24h GH elevation
- Increased IGF-1
- Improved sleep depth
- Enhanced recovery
- Bone density support
Somatropin (HGH) reported benefits
- Fat loss (especially visceral)
- Increased lean muscle mass
- Improved sleep quality
- Faster recovery from injury
- Improved skin elasticity
- Increased bone density
- Enhanced cognitive function
Related comparisons
Research and educational reference only. Not medical advice.